Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area
Executive Summary
Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.
You may also be interested in...
Pulling Back The Curtain On Biopharma Partnering In Cell And Gene Therapies
Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.
Biogen Builds Out Parkinson's Pipeline With Denali Deal
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Astellas To Pay $3bn For Gene Therapy Company Audentes
Japanese company joins the ranks of big pharma buying up gene therapy pioneers
Need a specific report? 1000+ reports available
Buy Reports